AI Stock Memo: TPST - Tempest Therapeutics - RankAlpha

TPST

Rating neutralAI Memo

Tempest Therapeutics

As of 2026-06-03/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-06-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

6/2 warrant issuance adds dilution overhang • 2026-06-02

Expected move: +11%

Biggest risk

The bear case is classic micro-cap biotech dilution and execution risk: the stock is sub-$25M market cap, recent financing/warrant activity can cap rallies, and value is concentrated in one lead program with limited independent validation.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

Company-reported TPST-2003 data remain the core bull story: 100% CR among 15 CAR-T-naive efficacy-evaluable patients across REDEEM-1/POEMS-1, no Grade >=3 CRS or ICANS in REDEEM-1, and the AGCTC manufacturing setup keeps the planned U.S. registrational study on track [#SEC-8K-2026-05-14].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-06-03

Base target

p=55%

Bull target

p=20%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

TPST-2003 data and manufacturing prep support registrational path
Partnering and BD optionality expand longer-term upside
Company-reported TPST-2003 data remain the core bull story: 100% CR among 15 CAR-T-naive efficacy-evaluable patients across REDEEM-1/POEMS-1, no Grade >=3 CRS or ICANS in REDEEM-1, and the AGCTC manufacturing setup keeps the planned U.S.

BearKey bullets

Dilution and price overhang from recent and potential warrant-linked financing.
Low analyst and recent-news coverage means sentiment can reprice abruptly on limited information.
Single-asset concentration leaves little diversification if interim efficacy does not hold up.

WatchKey bullets

6/2 warrant issuance adds dilution overhang

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=55%)

Bull/Bear spread: +114% / -54%

Vs latest close: Bull +114% · Base +11% · Bear -54%

Scenario probabilities

Bull Target: $3 (p=20%)Base Target: $1 (p=55%)Bear Target: $1 (p=25%)

Commentary

This is a filing-led, low-coverage biotech tape rather than a sentiment-driven one. The 6/2 warrant filing adds a near-term dilution/watch item, while the 5/14 business update keeps TPST-2003 clinically relevant; with no recent news flow, no social context, and no fresh analyst revisions, confidence should stay cautious.

As of 2026-06-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

TPST-2003 data and manufacturing prep support registrational path
Partnering and BD optionality expand longer-term upside

Scenarios

Bull Target (Scenario probability)

$3 / p=20% prob

Base Target (Scenario probability)

$1 / p=55% prob

Bear Target (Scenario probability)

$1 / p=25% prob

Price $1 as of 2026-06-02

Nearest Scenario: Base (∆ 11%)

Targets vs latest close: Bull +114% · Base +11% · Bear -54%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-06-02
6/2 warrant issuance adds dilution overhang
Tempest's 6/2 8-K disclosed a New Warrant with a $1.73 exercise price, exercisable only after required Nasdaq stockholder approval, which keeps a financing and dilution overhang on the stock [#SEC-8K-2026-06-02].
Prob 80.00% • Move 12.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

TPST-2003 data and manufacturing prep support registrational path
2026-12-31
The 5/14 quarter update confirmed positive interim TPST-2003 data, a 100% complete response rate among CAR-T-naive efficacy-evaluable patients, no Grade >=3 CRS or ICANS in REDEEM-1, and AGCTC as lead manufacturing partner ahead of the planned U.S. registrational study later in 2026 [#SEC-8K-2026-05-14].
Prob 55% • Move 60% • Priced-in 30%
Partnering and BD optionality expand longer-term upside
2027-12-31
Tempest's March asset acquisition and May appointment of a Head of Business Development reinforce a partner-funded development model, including a China BLA plan for TPST-2003 in 2027 and broader licensing/transaction optionality [#SEC-8K-2026-03-30] [#SEC-8K-2026-05-14].
Prob 35% • Move 20% • Priced-in 20%

Risks

Dilution and price overhang from recent and potential warrant-linked financing.
Low analyst and recent-news coverage means sentiment can reprice abruptly on limited information.
Single-asset concentration leaves little diversification if interim efficacy does not hold up.
TPST-2003 is still early-stage; registrational plans can slip on manufacturing, enrollment, or safety.

Peers

Symbol	Summary
CRIS	Same-sector micro-cap biotech comparator with similar event-driven volatility and financing sensitivity; useful mainly for runway and catalyst-risk framing.
HOWL	Another small-cap biotech peer in a similar market-cap band; comparable for binary clinical/news reaction rather than steady operating metrics.
TRAW	Same-sector low-cap therapeutic peer with overlapping dilution sensitivity and catalyst-driven trading dynamics.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-06-03